3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
6
Neoplasms
2
Stomatitis
1
Solitary Pulmonary Nodule
1
Shock, Septic
1
Pain, Postoperative
1
Neoplasm Metastasis
1
Multiple Pulmonary Nodules
1
Melanoma
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Emergence Delirium
1
Disease
1
Colorectal Neoplasms
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
Methylene Blue
×
Clear all
NCT02057393
2017-07-06
SPY-SN
Milton S. Hershey Medical Center
Phase NA
Completed
89 enrolled
3 charts